Other languages BerGenBio ASA

Equities

BGBIO

NO0013251173

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-07-12 am EDT			5-day change	1st Jan Change
12.18 ^NOK	-2.95%		+6.28%	-56.19%

May. 29	BerGenBio ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 29	Transcript : BerGenBio ASA, Q1 2024 Earnings Call, May 29, 2024

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BerGenBio ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 29
BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB	May. 28
Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation	Mar. 20
BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14
BerGenBio ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14
BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections	Feb. 07
BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients	Dec. 15
BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting	Dec. 11
BerGenBio ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Bergenbio Announces Data from Biomarker Analyses in 2L Nsclc	Nov. 06
BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer	23-10-23
Virax Biolabs Group Names Nigel McCracken Operating Chief.	23-09-01
BerGenBio ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23
BerGenBio ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-22
BerGenBio Drug Reduces Cancer Signs in Mid-stage Study	23-06-06
BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO	23-06-05
BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors	23-05-22
BerGenBio ASA Presents Data on STK11 Loss of Function and AXL Activation at AACR	23-04-18
BerGenBio ASA Announces First Patient Dosed In Phase 1B/2A Trial Evaluating Bemcentinib In 1St Line Non-Small Cell Lung Cancer With Stk11 Mutations	23-03-09
BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BerGenBio ASA

Equities

BGBIO

NO0013251173

Other languages

Filters